Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.65 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.56 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.55 |
| ▸ | GBA1 | P04062 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22701235 | 1.00 | CYP19A1 (0.65) | CYP19A1HRH4HRH3GGPS1GBA1 | |
| SCHEMBL25836828 | 1.00 | CYP19A1 (0.65) | CYP19A1HRH4HRH3GGPS1GBA1 | |
| SCHEMBL22794232 | 1.00 | CYP19A1 (0.65) | CYP19A1HRH4HRH3GGPS1GBA1 | |
| SCHEMBL3546675 | 1.00 | CYP19A1 (0.65) | CYP19A1HRH4HRH3GGPS1GBA1 | |
| SCHEMBL3549774 | 0.98 | CYP19A1 (0.62) | CYP19A1HRH4HRH3GGPS1GBA1 | |
| SCHEMBL5021080 | 0.92 | L3MBTL1 (0.56) | CYP19A1HRH4HRH3GGPS1GBA1 | |
| SCHEMBL14982736 | 0.88 | CYP19A1 (0.50) | CYP19A1HRH4HRH3GGPS1GBA1 | |
| SCHEMBL24675720 | 0.87 | HRH4 (0.66) | CYP19A1HRH4HRH3GBA1EPHX2 | |
| SCHEMBL21318217 | 0.87 | HRH4 (0.66) | CYP19A1HRH4HRH3GBA1EPHX2 | |
| SCHEMBL9926292 | 0.87 | CYP19A1 (0.63) | CYP19A1HRH4HRH3GBA1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | CYP19A1 3592/4885HRH4 3850/4885HRH3 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.